Scientists Advancing Affordable Medicines, Inc. is a nonprofit 501(c)(6) organization that seeks to provide a dedicated platform for scientists to share cutting-edge research that facilitates the development of high-quality, affordable medicines, thereby improving their accessibility to patients. Because we are sharing approaches now for the affordable medicines of tomorrow, we have adopted the tradename SAAMnow.
Cutting Edge Approaches for Demonstrating Bioequivalence
April 16 – 17, 2020
Hilton Washington DC/Rockville Hotel
1750 Rockville Pike,
Rockville, MD 20852
Scientists Advancing Affordable Medicines, Inc. is excited to present a two-day event on transforming generic drug R&D using cutting edge approaches.
- – Scientific committee co-chaired by SAAMnow and FDA
- – Key note speakers on transforming generics R&D and use of model informed drug design for BE
- – Well represented by multiple FDA offices as speakers/panel-members/moderators
- – Panel discussions after each session with speakers and experts
SAAMnow offers individuals the opportunity to potentially impact the availability of affordable medicines through cutting-edge research. SAAMnow is looking for individuals involved/interested in research & development, formulation/manufacturing science, analytical chemistry, clinical science, statistics, quality systems, regulatory science, marketing, and allied disciplines associated with the development, manufacturing, testing, and commercialization of high quality affordable medicines. Affordable medicines are broadly defined as those that take advantage of abbreviated regulatory filing pathways, resulting in development cost savings that can then be passed on to patients. Examples include conventional generic pharmaceuticals, biosimilars, and products filed via hybrid regulatory pathways, such as the 505(b)(2) route.